CAS 65114-55-8

(2R)-2-[(12-{[(1E)-2-diazonio-3,3,3-trifluoro-1-oxidoprop-1-en-1-yl]oxy}dodecanoyl)oxy]-3-(hexadecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphate

Description:

The chemical substance with the name "(2R)-2-[(12-{[(1E)-2-diazonio-3,3,3-trifluoro-1-oxidoprop-1-en-1-yl]oxy}dodecanoyl)oxy]-3-(hexadecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphate" and CAS number "65114-55-8" is a complex amphiphilic molecule characterized by its long hydrophobic fatty acid chains and a hydrophilic phosphate group. This structure suggests that it may function as a surfactant or emulsifier, potentially useful in various applications such as drug delivery systems or as a component in liposomal formulations. The presence of a diazonium group indicates potential reactivity, which could be exploited in chemical synthesis or modification processes. Additionally, the trimethylammonio group contributes to its cationic nature, enhancing solubility in aqueous environments and interaction with negatively charged biological membranes. Overall, this compound's unique structural features position it as a versatile agent in biochemical and pharmaceutical contexts, although specific applications would depend on further empirical studies and characterization.

Formula: C₃₉H₇₁F₃N₃O₁₀P

InChI: InChI=1/C39H71F3N3O10P/c1-5-6-7-8-9-10-11-12-13-15-18-21-24-27-35(46)52-32-34(33-54-56(49,50)53-31-29-45(2,3)4)55-36(47)28-25-22-19-16-14-17-20-23-26-30-51-38(48)37(44-43)39(40,41)42/h34H,5-33H2,1-4H3/b38-37+/t34-/m1/s1

1-Palmitoyl-2-ω-(2-Diazo-3,3,3-Trifluoropropionyloxy)Lauroyl-Sn-Glycero-3-Phosphocholine

CAS: 65114-55-8

1-Palmitoyl-2-omega-(2-Diazo-3,3,3-Trifluoropropionyloxy)Lauroyl-Sn-Glycero-3-Phosphocholine is a potential therapy for pulmonary fibrosis. It is an admixture of two phospholipids containing the fatty acid palmitic acid and omega-(2,3,3,3,-trifluoroethoxy)acetyl lauroylglycerophosphocholine. The molecule is activated by carbon monoxide (CO), which converts it to a form that can be taken up by cells. CO has been shown to inhibit the growth of cells in culture and in animal models of pulmonary fibrosis. Treatment with the molecule also inhibits production of galacturonic acid and oligosaccharides from lysophosphatidylethanolamine and its derivatives.

Formula: C₃₉H₇₁F₃N₃O₁₀P

Purity: Min. 95%

Molecular weight: 829.96 g/mol

Ref: 3D-FP101867